The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Apr. 13, 2016
Applicant:

Irx Therapeutics, Inc., New York, NY (US);

Inventors:

James E. Egan, Stony Brook, NY (US);

Martin Kast, La Canada, CA (US);

Harvey Brandwein, East Hills, NY (US);

Assignee:

IRX Therapeutics, Inc., New York, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 31/405 (2006.01); A61K 31/664 (2006.01);
U.S. Cl.
CPC ...
A61K 38/217 (2013.01); A61K 9/0019 (2013.01); A61K 31/405 (2013.01); A61K 31/664 (2013.01); A61K 31/675 (2013.01); A61K 38/191 (2013.01); A61K 38/193 (2013.01); A61K 38/204 (2013.01); A61K 38/2006 (2013.01); A61K 38/208 (2013.01); A61K 38/2013 (2013.01); A61K 38/2046 (2013.01); A61K 38/2053 (2013.01); A61K 38/2086 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01);
Abstract

A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.


Find Patent Forward Citations

Loading…